A scoring model of factors associated with Candida glabrata candidemia among critically ill patients

Mycoses

Volumn 55, Issue 3, 2012, Pages 228-236

  Tapia, Gino G ^a   Razonable, Raymund R ^b   Eckel Passow, Jeanette E ^c   Lahr, Brian D ^c   Afessa, Bekele ^b   Keegan, Mark T ^b   Catania, Jelena ^d   Baddour, Larry M ^b  

^a Sanford Health ^*  (United States)

^b MAYO CLINIC   (United States)

^c Mayo Clinic   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Candida glabrata; Candidemia; Intensive care unit; Scoring model

Indexed keywords

FLUCONAZOLE;

ABDOMINAL SURGERY; ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA GLABRATA; CANDIDA GLABRATA CANDIDEMIA; CANDIDEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; HOSPITAL ADMISSION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDEMIA; FEMALE; FLUCONAZOLE; HUMANS; INTENSIVE CARE UNITS; LOGISTIC MODELS; MALE; MIDDLE AGED; MINNESOTA; RETROSPECTIVE STUDIES; YOUNG ADULT;

CANDIDA; CANDIDA GLABRATA;

EID: 84859051591     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02069.x     Document Type: Article

References (44)

1. Vincent JL, Sakr Y, Sprung CL et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344-53.
2. Vincent JL, Rello J, Marshall J et al. International Study of the Prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-9.
3. Lewis RE. Overview of the changing epidemiology of candidemia. Curr Med Res Opin 2009; 25: 1732-40.
4. CDC and Prevention. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-June 2001. Am J Infect Control 2001; 29:404-21.
5. Pappas PG. Invasive candidiasis. Infect Dis Clin N Am 2006; 20: 485-506.
6. Pfaller MA, Diekema DJ, Gibbs DL et al. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010; 67: 162-71.
7. Playford EG, Lipman J, Sorrell T. Management of invasive candidiasis in the intensive care unit. Drugs 2010; 70: 823-39.
8. Sobel JD. The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. Curr Infect Dis Rep 2006; 8: 427-33.
9. Gottfredsson M, Vredenburgh JJ, Xu J, Schell WA, Perfect R. Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation. Cancer 2003; 98: 24-30.
10. Drew RH. Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis?. Ann Pharmacother 2007; 41: 690-2.
11. Shorr AF, Lazarus DR, Sherner JH et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia Crit Care Med 2007; 35: 1077-83.
12. Bodey GP, Mardani M, Hanna HA et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 112: 380-5.
13. Cohen Y, Karoubi P, Adrie C et al. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients. Crit Care Med 2010; 38: 826-30.
14. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366-77.
15. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard. NCCLS document M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
16. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
17. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycosis Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
18. Al-Tawfiq JA. Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital, 1996-2004. Int J Infect Dis 2007; 11: 239-44.
19. Weinberger M, Leibovici L, Perez S et al. Characteristics of candidemia with Candida albicans compared with non-albicans Candida species and predictors of mortality. J Hosp Infect 2005; 61: 146-54.
20. Goodrich JM, Reed EC, Mori M et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164: 731-40.
21. Barberino MG, Silva N, Reboucas C et al. Evaluation of bloodstream infections by Candida in three tertiary hospitals in Salvador, Brazil: a case-control study. Braz J Infect Dis 2006; 10: 36-40.
22. Amratkumar PP, Chen RH, LaRocco MT, Gentry LO, Garey KW. Comparison of risk factors for candidemia versus bacteremia in hospitalized patients. Infection 2006; 34: 322-7.
23. Bassetti M, Trecarichi EM, Righi E et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007; 58: 325-31.
24. Konshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989; 11: 379-90.
25. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteremia. Int J Antimicrob Agents 1999; 11: 7-12.
26. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.
27. Efron B, Gong G. A leisurely look at the bootstrap, the jackknife, and cross-validation. Am Stat 1983; 37: 36-48.
28. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 1992; 11: 2093-109.
29. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001; 165: 119-25.
30. Leibovich BC, Cheville JC, Lohse CM et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005; 174: 1759-63.
31. Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients. Ann Pharmacother 2007; 41: 568-73.
32. Cheng MF, Yang YL, Yao TL et al. Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species. BMC Infect Dis 2005; 5: 22.
33. Ostrosky-Zeichner L, Sable C, Sobel J et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26: 271-6.
34. Ostrosky-Zeichner L, Pappas PG, Shoham S et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 2011; 54: 46-51.
35. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005; 43: 235-43.
36. León C, Ruiz-Santana S, Saavedra P et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37: 1624-33.
37. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
38. Le Gall JR, Alberti C, Brun Buisson C. Epidemiology of infection and sepsis in intensive care unit patients. Bull Acad Natl Med 2004; 188: 1115-25.
39. Alberti C, Brun-Buisson C, Burchardi H et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002; 28: 108-21.
40. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
41. Morrell M, Fraser V, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
42. Sofair AN, Lyon GM, Huie-White S et al. Epidemiology of community-onset candidemia in Connecticut and Maryland. Clin Infect Dis 2006; 43: 32-39.
43. Kung HC, Wang JL, Chang SC et al. Community-onset candidemia at a university hospital, 1995-2005. J Microbiol Immunol Infect 2007; 40: 355-63.
44. Rhee JY, Kwon KT, Ki HK et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation in scoring systems. Shock 2009; 31: 146-50.